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Abstract
Immunoparesis and a skewed serum free light chain (FLC) ratio are indicators of immune 
dysfunction predictive of progression from monoclonal gammopathy of undetermined significance 
(MGUS) to multiple myeloma (MM). Previous studies have reported increased prevalence of 
MGUS by age, but no study has examined the relationship between immunoparesis and abnormal 
FLC ratios in the elderly. We screened 453 older adults (median age 80, range 65–96) to 
characterize patterns of immunoparesis and abnormal FLC ratio in relation to MGUS. We defined 
MGUS in 4.4% of the subjects; the prevalence was 12.5% among individuals >90 years. In MGUS 
(versus non-MGUS) cases, immunoparesis and abnormal FLC ratios were detected in 70.0% 
(versus 49.0%; p=0.07) and 50.0% (versus 12.9%; p=0.0001), respectively. Based on small 
numbers, MGUS patients with abnormal FLC ratio were borderline (p=0.07) more likely to have 
immunoparesis. Overall, the prevalence of immunoparesis varied in a non-linear fashion, with 
lowest frequencies in the youngest and oldest groups. Our observed disassociation between MGUS 
prevalence and impaired immunoglobulin production suggests that separate mechanisms are 
involved in the development of MGUS and immunoparesis in advanced age. These findings 
emphasize the need for molecularly defined methods to characterize myeloma precursor states and 
better predict progression to MM.
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Advanced age is associated with altered immune function and increased incidence of cancer, 
and there is evidence for interaction between these phenomena.[1] The plasma cell 
malignancy multiple myeloma (MM) is primarily a disease of older people, with median age 
at diagnosis of approximately 70 years.[2] MM consistently evolves from the precursor state 
monoclonal gammopathy of undetermined significance (MGUS),[3] characterized by 
production of a clonal immunoglobulin and diagnosed by finding of a narrow monoclonal 
protein band on serum or urine protein electrophoresis. The Mayo Clinic has determined the 
prevalence of MGUS to be approximately 3% in whites aged 50 years or older,[4] and in 
follow-up studies has reported serum free light chain (FLC) abnormalities to be present in 
this group among persons with and without “conventional” heavy chain MGUS, increasing 
the overall prevalence of MGUS to approximately 4%.[5]
Results from several population-based studies have shown that the prevalence of MGUS 
increases with age.[4–7] As indicated by its name, MGUS is associated with an uncertain 
risk of progression to MM and related disorders,[8] and clinical markers of immune 
dysfunction including immunoparesis (uninvolved immunoglobulin levels below the lower 
limit of normal) and skewed serum FLC ratio have been proposed as significant indicators to 
predict progression to malignant disease.[9, 10] Racial and ethnic characteristics have been 
shown to play a role in immunoglobulin production[11] and incidence of plasma cell 
dyscrasias,[2, 12] but there is limited information on the role of advanced age in these 
conditions. To further investigate the patterns of immunoparesis and altered immunoglobulin 
production in advanced age, we have conducted a screening study in a group of older adults 
(n=453; age ≥65 years), with a median age of 80 years.
Methods
Blood samples (n=453) were included from a prior study[13] that evaluated persons aged 
≥65 years at Mount Sinai Hospital, New York City, from February to December, 2000. The 
study over-sampled Jewish subjects to examine correlates of human herpes virus-8 infection. 
Following a uniform protocol, subjects answered questions regarding demographic 
information and medical history and provided a blood sample. Participating subjects 
provided informed consent. This study was approved by institutional review boards at the 
National Cancer Institute and Mount Sinai Hospital. Briefly, plasma and cells were 
separated by the prior investigators within 24 hours of phlebotomy and stored at −70°C. 
Following all analyses for the prior study, samples were transferred to our institution via 
cold storage.
At our laboratory, samples were subjected to protein electrophoresis using a Helena SPIFE 
3000 system (Helena Laboratories, Beaumont, TX). Gels were scanned on a V7000 scanner 
with Helena Laboratories software for identification and quantification of M-protein. Kappa 
and lambda FLC values were measured with a SPAplus specialist protein analyzer (The 
Binding Site, Birmingham, UK), and FLC ratios outside our reference range (0.26–1.65) 
were considered abnormal. Samples that demonstrated an M-protein band or abnormal FLC 
ratio were subjected to immunofixation electrophoresis. Samples that demonstrated clonality 
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were classified as MGUS, and major immunoglobulin isotypes (i.e. IgG, IgA, and IgM) 
were quantified for all samples. Immunoglobulins were quantified using a SPAPlus 
automated analyzer (The Binding Site, Birmingham UK). Per the manufacturer (using non-
parametric statistics and representing 95% of the central population), the reference ranges 
are as follows: IgG: 610–1616; IgA: 84–499; and IgM: 35–242. Immunoparesis was defined 
as one or more immunoglobulins less than the lower limit of normal for our laboratory’s 
respective reference range. Statistical calculations were performed using Microsoft Excel 
and IBM SPSS Statistics 20; all significance tests were two-tailed unless otherwise 
specified.
Results
Among the 453 individuals ≥65 years of age, 150 (33.1%) were males and 303 (66.9%) were 
females, with ages ranging from 65.1 to 95.7 years and a median age of 79.9 years. Racial 
makeup of the group was 300 (66.2%) white, 106 (23.4%) black, 41 (9.1%) Hispanic, and 6 
(1.3%) other race. The findings of MGUS, immunoparesis, and abnormal FLC ratio among 
all 453 persons are summarized in Table I.
MGUS
Overall, we found 4.4% of samples to meet criteria for MGUS. The median ages in the 
MGUS and non-MGUS groups were 82.0 years and 79.7 years, respectively; other 
comparisons are summarized in Table II. Eighteen cases (90%) of MGUS consisted of a 
single paired heavy-light chain monoclonal protein, and in two cases (10%), two monoclonal 
proteins were identified. The distribution of gamma-globulin isotypes IgG, IgA, and IgM 
was 55%, 14%, and 32%, respectively.
The prevalence of MGUS was similar between men (4.7%) and women (4.3%) and 
increased by age, with a prevalence of 12.5% among persons older than 90 years (Figure 1). 
Overall, MGUS was present in 4.7% of samples from whites, 4.7% of samples from blacks, 
and 2.4% of samples from Hispanics. Among patients with MGUS, the prevalence of 
abnormal FLC ratio was 50.0%, and the prevalence of immunoparesis was 70.0%. Based on 
small numbers, MGUS patients with abnormal FLC ratio were borderline (p=0.07) more 
likely to also have immunoparesis (Table III).
Immunoparesis
The overall prevalence of immunoparesis was 49.9%, and prevalence was similar between 
men (47.3%) and women (51.2%). The prevalence of immunoparesis across age groups 
followed a non-linear pattern (Figure 1). Prevalence was lowest in the youngest (65–70 
years) and oldest (>90 years) age groups at 42.5%, and was highest among persons aged 80–
85 years at 56.2%. Immunoparesis was detected among 56.0% of whites, 41.5% of blacks, 
31.7% of Hispanics, and 16.7% among samples designated as other race. Among non-
MGUS cases with immunoparesis (n=212), we found depression of one, two, or three 
immunoglobulins in 144, 57, and 17 cases, respectively. The IgG, IgA, and IgM isotype was 
depressed in 65%, 27%, and 48% of these non-MGUS cases, respectively. Immunoparesis 
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was identified in 70.0% of MGUS samples and in 49.0% of non-MGUS samples, and there 
was a trend toward an association of immunoparesis and MGUS (p=0.07).
Abnormal FLC ratio
The overall prevalence of abnormal FLC ratio was 14.6%, and prevalence was similar 
between men (14.0%) and women (14.9%). The prevalence of abnormal FLC ratio doubled 
from 10.0% in the youngest age group (65–70 years) to 20.0% in the oldest age group (>90 
years). Abnormal FLC ratios were found among 11.3% of whites, 25.5% of blacks, and 
12.2% of Hispanics. Abnormal FLC ratios were present in 50.0% of MGUS samples and in 
12.9% of non-MGUS samples, and this comparison was highly significant (p=0.0001). 
Similar to the original study by Rajkumar et al. showing that an abnormal FLC ratio is a 
significant predictor of progression to MM, kappa to lambda FLC ratios outside our 
reference range (0.26–1.65) were considered abnormal [10]. A small proportion of cases 
(9%) with an abnormal FLC ratio were due only to suppression of one of the two light 
chains. The remaining 91% were due to relative elevation of one of the two light chains.
Discussion
This study of older adults (≥65 years; median age 80 years) expands on prior investigations 
showing that the prevalence of MGUS increases by age.[4–7] In our oldest age group 
including people older than 90 years, the prevalence of MGUS was 12.5%. The oldest age 
group (>80 years) reported by the Mayo Clinic had an MGUS prevalence of 6.6%.[4] We 
found the prevalence of MGUS to be 4.7% for both blacks and whites, in contrast to a 
previous large study that showed a three-fold higher age-adjusted prevalence of MGUS for 
blacks relative to whites.[12] However, racial disparities in gammopathies are most 
pronounced in younger people and become less apparent with age,[2] which may partly 
explain our finding of similar MGUS prevalence in this older population of whites (median 
age, 80.7 years) and blacks (median age, 78.4 years).
Previous studies of immune function in aging have focused on changes in hematopoietic 
stem cells, immune organs and T cell functionality,[14–17] but to our knowledge this is the 
first systematic investigation of immune changes in advanced age by analysis of 
immunoglobulin production patterns. Immunoparesis was highly prevalent (49.9%) in our 
sample and interestingly, our results showed an inverted “U” pattern in which prevalence of 
immunoparesis was lowest in the youngest age group (65–70 years) at 42.5%, peaked at 
56.2% in the 80–85 age group and declined successively to 42.5% in the oldest age group 
(>90 years). Genetic[17] and microenvironmental[18] factors related to aging may be 
responsible for changes in hematopoietic stem cell populations that select for myeloid 
precursor cells and result in a relative decrease of lymphoid progenitors, and centenarian 
studies have shown that the linear decline of lymphocyte numbers continues with advancing 
age.[19] However, studies of these “oldest old” have also found that rates of metabolic, 
inflammatory, and immune dysfunction decrease in very old age.[20, 21] Our observation 
that immunoparesis peaks with advancing age but declines among very old individuals adds 
to our evolving understanding of the relationship between immune cell number and function 
in the very old.
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There was a racial disparity in the prevalence of immunoparesis, which was present in 
56.0% of samples from whites and 41.5% of samples from blacks. The original study 
sample[13] was enriched for Ashkenazi Jewish individuals, a group genetically predisposed 
to development of autoimmune and other diseases,[22] and this may partly explain the 
disparity observed in our study. Other differences in baseline immunoglobulin production 
have been reported across racial groups,[11] and we were not able to provide molecular 
details to further characterize these differences.
The overall prevalence of abnormal FLC ratio was 14.6% in our sample compared to 3.3% 
in a prior population-based study of light chain abnormalities.[5] Among persons with 
MGUS, we found an abnormal FLC ratio in 50%, an increase from the 33% prevalence 
reported by the Mayo Clinic.[10] Individuals with and without MGUS in our study were 
older (median ages of 82 and 80 years, respectively) than those in the Mayo conventional 
and light chain MGUS studies (median ages of 72 and 70 years, respectively), and the 
increased prevalence of abnormal FLC reported here may be due to increasing plasma cell 
dysfunction in advancing age or to the effect of an age-related factor. Renal disease, for 
example, may differentially alter kappa and lambda excretion rates, significantly influencing 
both levels of circulating light chains[23, 24] and the FLC ratio. Such an age-related factor 
may work in concert with plasma cell dysfunction to account for the higher prevalence of 
abnormal FLC ratio observed among these older individuals.
The Mayo Clinic has reported that a skewed FLC ratio is a significant predictor of 
progression to MM but that risk of progression to MM is stable over time and unrelated to 
age at diagnosis of MGUS.[10] The Spanish PETHEMA group, by contrast, has previously 
shown that presence of immunoparesis is significantly associated with progression from 
smoldering MM to MM and is a borderline significant risk factor in MGUS.[9] In this study, 
we show that advancing age is linked to immune changes represented by waxing and waning 
frequency of immunoparesis in a population of older individuals, but that prevalence of 
MGUS increases with advancing age. Clinical management strategies based on predictive 
models inform patient counseling and follow-up, and additional investigations are needed to 
better characterize the role of immunoparesis as a risk factor for transformation to MM in 
relation to age.
In summary, in this population of older people, we found a striking disassociation between 
prevalence patterns of MGUS and impaired immunoglobulin production, suggesting that 
separate mechanisms are involved in the development of MGUS and immunoparesis in 
advanced age. Compared to previous studies of younger MGUS patients, we found older 
MGUS patients to have a substantially higher prevalence of abnormal FLC ratio (33% vs. 
50%, respectively). Given that immunoparesis and a skewed FLC ratio are included in 
current clinical risk models to predict transformation from myeloma precursor states to MM,
[9, 10] our findings further emphasize the need for molecularly and genetically defined 
predictors of progression.[25]
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Table II
Prevalence of immunoparesis and abnormal FLC ratios in 453 elderly persons by MGUS status
Parameter MGUSPrevalence % (95% CI)
Non-MGUS







Abnormal FLC ratio 1050.0 (27.2–72.8)
56
12.9 (9.9–16.5)






No immunoparesis 630.0 (11.9–54.3)
221
51.0 (46.2–55.8) 0.07
Both immunoparesis and abnormal FLC ratio 945.0 (23.1–68.5)
28
6.5 (4.3–9.2)
No immunoparesis, normal FLC ratio 525.0 (8.7–49.1)
193
44.6 (39.8–49.4) <0.0001
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Table III
Immunoparesis among 20 elderly persons with MGUS and with presence or absence of abnormal FLC ratio
Parameter MGUS with abnormal FLC ratio MGUS without abnormal FLC ratio P-value
Total number 10 10
Immunoparesis 9 5
No immunoparesis 1 5 0.07*
*
Fisher exact (1-tailed) test
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